Author

Chandhana Ravi

University of Rochester Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Cameron W. A. SnyderiD· 2 shared Elizabeth A. LaMere· 2 shared Kyukwang KimiD· 2 shared Myla S. StrawdermaniD· 2 shared Negar KhazaniD· 2 shared Nikolay V. DokholyaniD· 2 shared Niloy A. Singh· 2 shared Rachael B. Rowswell-TurneriD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Cameron W. A. SnyderORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9

Negar Khazan, Cameron W. A. Snyder, Nicole Dawney, Elizabeth A. LaMere, Srinivasan Ekambaram, Niloy A. Singh, Chandhana Ravi, Rajiv Snape, Hannah E. Aichelman, Elizabeth Pritchette, John M. Ashton, Thomas Kay, Myla S. Strawderman, Naohiro Yano, Dan T. Bergstralh, , Rakesh K. Singh

This paper demonstrates that UR214-9 disrupts septin hetero-octamerization, leading to aberrant structures and impairing cancer cell functions.

bioRxiv · Jun 9, 2026 · PreprintCancer Biology

PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML

Negar Khazan, Cameron W. A. Snyder, Chandhana Ravi, Elizabeth A. LaMere, Niloy A. Singh, Manoj Kumar Khera, Jane L. Liesveld, Srinivasan Ekambaram, Nikolay V. Dokholyan, Myla S. Strawderman, Kyukwang Kim, Rachael B. Rowswell-Turner, Michael W. Becker, Richard G. Moore, Rakesh K. Singh

This study identifies PSP-0119, an IRAK4 degrader, as a promising therapy for FLT3-mutant AML by inhibiting IRAK4 activity and showing antileukemic effects in cell lines and xenograft models.

bioRxiv · Sep 30, 2025 · PreprintCancer Biology